Comparative Pharmacology
Head-to-head clinical analysis: ASPARLAS versus DEPOCYT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASPARLAS versus DEPOCYT.
ASPARLAS vs DEPOCYT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Asparaginase (ASPARLAS) hydrolyzes L-asparagine to L-aspartic acid and ammonia, depleting circulating asparagine. Leukemic cells with low asparagine synthetase activity rely on exogenous asparagine; depletion inhibits protein and nucleic acid synthesis, leading to cell death.
Cytarabine is a nucleoside analog that inhibits DNA polymerase, leading to termination of DNA chain elongation and cell death in the S phase of the cell cycle.
Intravenous (IV) or intramuscular (IM) injection: 2,500 IU/m² every 14 days as a component of multi-agent chemotherapy. Administer IV over 1-2 hours in 100 mL of 0.9% sodium chloride.
50 mg intrathecally via lumbar puncture or intraventricularly via Ommaya reservoir on days 1, 15, 29, 43, 57, 71, 85, and 99 for induction; followed by consolidation and maintenance doses. Administer with dexamethasone 4 mg PO/IV twice daily for 5 days starting on the day of DepoCyt injection.
None Documented
None Documented
The terminal elimination half-life is approximately 25.7 days (range 17.8–33.6 days) in children and 22.0 days in adults, allowing for dosing every 2 weeks instead of 3 times per week as with native E. coli asparaginase.
After intrathecal administration, the terminal half-life of cytarabine in CSF is 2.5-4.5 hours (mean 3.5 hours) due to slow clearance from CSF; systemic half-life is 10-15 minutes due to rapid deamination.
Calaspargase pegol (ASPARLAS) is eliminated via the reticuloendothelial system; renal excretion is negligible (<2% unchanged), and biliary/fecal excretion has not been quantified. The pegylated asparaginase is cleared through proteolytic degradation.
Renal excretion of cytarabine metabolites accounts for >70% of elimination; unchanged cytarabine excretion is minimal (<10%). Biliary/fecal excretion is negligible (<5%).
Category C
Category C
Antineoplastic, Enzyme
Antineoplastic